Global blood therapeutics, inc. (GBT)
CashFlow / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss

-266,766

-174,193

-117,024

-82,468

-46,360

-20,807

-18,116

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization

8,605

4,607

1,658

1,160

873

666

534

Amortization (accretion) of premium (discount) on marketable securities

2,057

661

-704

-75

-

-

-

Non-cash interest expense

43

-

-

-

-

-

-

Amortization of operating lease right-of-use assets

1,327

-

-

-

-

-

-

Remeasurement of Series A redeemable convertible preferred stock liability

-

-

-

-

-

-297

-2,500

Stock-based compensation

45,651

30,080

13,682

9,235

3,223

350

138

Gain on lease modification

8,301

-

-

-

-

-

-

Loss from disposal of fixed assets, net

-

-45

-

-

-33

-

-

Fair value of stock issued for license

-

-

-

-

4,492

-

0

Changes in operating assets and liabilities:
Accounts receivables

2,637

-

-

-

-

-

-

Inventories

1,277

-

-

-

-

-

-

Prepaid expenses and other assets

3,085

2,500

1,856

761

87

753

73

Other assets, current

2,112

1,278

162

512

-22

323

-149

Accounts payable

4,499

-1,285

2,771

1,066

2,705

-304

-465

Payable due to related party

-

-

-

-

-14

-115

-68

Accrued liabilities

24,706

8,031

3,280

1,794

2,834

599

183

Accrued compensation

7,543

1,457

3,612

2,725

1,395

271

494

Other liabilities, current

-1,482

742

-63

23

19

17

38

Operating lease liabilities

893

-

-

-

-

-

-

Other liabilities

33

-420

376

-60

-25

-19

31

Net cash used in operating activities

-194,417

-135,375

-93,022

-67,723

-30,890

-20,121

-14,700

CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property and equipment

3,460

4,824

3,101

1,352

993

323

940

Sale of property and equipment

45

75

-

-

-

-

-

Purchase of marketable securities

434,919

361,405

127,724

105,500

-

-

-

Maturities of marketable securities

361,473

181,997

96,000

-

-

-

-

Increase in restricted cash

-

-

-

-

-

60

0

Purchases of other assets

-

-

175

-

-

-

-

Net cash provided by (used in) investing activities

-76,861

-184,157

-35,000

-106,852

-993

-383

-940

CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common stock in public offering, net

219,443

396,501

231,955

116,995

126,230

-

0

Proceeds from issuance of long-term debt, net of debt issuance costs

72,475

-

-

-

-

-

-

Proceeds from issuance of redeemable convertible preferred stock, net of issuance costs

-

-

-

-

-

68,838

15,235

Proceeds from sale of restricted stock

-

-

-

-

2,108

408

43

Proceeds from issuance of common stock in settlement of employee stock purchase plan and exercise of stock options

13,857

7,669

3,892

1,240

45

49

1

Repurchases of unvested restricted stock purchases

-

12

421

90

67

-

0

Tax paid related to net share settlement of equity awards

7,617

6,252

238

-

-

-

-

Net cash provided by financing activities

298,158

397,906

235,188

118,145

128,316

69,295

15,279

Net increase (decrease) in cash, cash equivalents and restricted cash

26,880

78,374

107,166

-56,430

96,433

48,791

-361

SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING INFORMATION:
Leasehold improvements paid for by landlord

17,231

-

11,086

-

-

-

-

Remeasurement and settlement of fair value of Series A redeemable convertible preferred stock liability

-

-

-

-

-

2,526

4,885

Accretion of Series A redeemable convertible preferred stock

-

-

-

-

4,180

2,965

1,735

Accrued purchase of property and equipment

78

48

1,536

114

-

-

-

Accrued issuance costs

85

467

-

-

-

-

-